Korean J Gynecol Oncol.  2006 Sep;17(3):183-187.

Cost-benefit issues about human papillomavirus (HPV) testing

Affiliations
  • 1National Cancer Center, Goyang, Korea. sokbom@ncc.re.kr

Abstract

Recently, a number of evidences that human papillomavirus (HPV) testing was efficient in cervical cancer screening were introduced. Moreover, successful trial outcome of preventive cancer vaccine opened new era of cervical cancer prevention. However, undoubtedly, applying new cancer screening and prevention strategy would bring on economical concern about increased medical expense. Therefore, appropriate cost-benefit analysis is very important before establishing new strategy as standard policy. In this article, we presented a few recent results about cost-benefit effectiveness by other group. And we also suggested what would be needed to perform successful.

Keyword

Cervical neoplasm; Human papillomavirus; Cancer screening; Cost-effectiveness; Vaccine; Cancer prevention

MeSH Terms

Cost-Benefit Analysis
Early Detection of Cancer
Humans*
Mass Screening
Uterine Cervical Neoplasms
Full Text Links
  • KJGO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr